Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.99 USD | +4.72% | +3.91% | -57.14% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 322M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -56M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.33
x | P/E ratio 2025 * |
-5.95
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp.
1 day | +4.72% | ||
1 week | +3.91% | ||
Current month | +9.32% | ||
1 month | -7.10% | ||
3 months | -28.43% | ||
6 months | -30.61% | ||
Current year | -57.14% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.04% | 1,487 M€ | +7.21% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 3.99 | +4.72% | 1,105,408 |
24-05-10 | 3.81 | -1.80% | 887,093 |
24-05-09 | 3.88 | +4.58% | 1,001,710 |
24-05-08 | 3.71 | -3.39% | 1,010,038 |
24-05-07 | 3.84 | 0.00% | 876,789 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.14% | 322M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- AVXL Stock